Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Adefovir-related nephrotoxicity by adefovir dose-reduction in HBV

A study in the latest issue of Alimentary Pharmacology & Therapeutics investigates resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B.

News image

Chronic hepatitis B patients treated with adefovir were followed up to evaluate nephrotoxicity and its outcome.

Dr Hartono and colleagues assessed the incidence of renal dysfunction during adefovir therapy in Asian patients and factors associated with it.

The team evaluated strategies to improve adefovir-related renal dysfunction, and their impact on viral suppression.

The researchers evaluated chronic hepatitis B clinic patients from a tertiary hospital on adefovir treatment.

The team extracted clinical and laboratory parameters from the hospital electronic clinical database in an observational study design.

Patients were excluded if they had liver/renal transplant, baseline renal impairment or were on dialysis.

The team of doctors defined adefovir-related renal dysfunction as adefovir-related abnormal serum creatinine as 125 μmol/L, 90 μmol/L for adefovir-related abnormal GFR 60 mL/min, and adefovir-related increased serum creatinine as 0.5 mg/dL, without other known causes of nephrotoxicity.

A total of 271 out of 383 adefovir-treated patients were suitable for analysis, and 33 patients developed abnormal serum creatinine.

Adefovir-related abnormal serum creatinine was 34%
Alimentary Pharmacology & Therapeutics

The research team found that cumulative increase in proportion of patients with adefovir-related abnormal serum creatinine was 34% and adefovir-related abnormal 60 mL/min was 38% by 6 years, while serum creatinine increase 0.5 mg/dL was 22% by 5 years.

Using multivariate analysis, the only independent baseline predictor of adefovir-related abnormal serum creatinine was adefovir-related abnormal 76.1 mL/min.

The team of doctors noted that patients who had adefovir-related abnormal serum creatinine had similar levels of viral suppression to those who did not have adefovir-related abnormal serum creatinine.

Those who had adefovir-related abnormal serum creatinine either continued adefovir, switched therapy or had adefovir dose reduction.

The researchers reported that adefovir-related abnormal serum creatinine resolved and adefovir-related abnormal normalised in almost all patients after either switching therapy or reducing adefovir dose, with no difference between the two strategies.

Those with adefovir dose reduction had no significant increase in HBV DNA.

Dr Hartono and his team commented, "Adefovir-related renal dysfunction occurred in a significant number of adefovir-treated patients, but reduction of the dose led to renal improvement without compromising treatment efficacy."

Aliment Pharmacol Ther 2013
04 March 2013

Go to top of page Email this page Email this page to a colleague

 06 March 2015

Advanced search
 06 March 2015 
Second anti-TNF in IBD
 06 March 2015 
Efficacy of Hep E vaccine
 06 March 2015 
Steroid therapy for eosinophilic esophagitis
 05 March 2015 
EPHXI polymorphism and esophageal cancer risk
 05 March 2015 
Infliximab and immunosuppressant therapy in ulcerative colitis
 05 March 2015 
Neuroendocrine carcinoma of the colon and rectum
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Management of IBD
 04 March 2015 
Progression of Barrett's
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 03 March 2015 
Risk of anastomotic leak after colectomy
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 02 March 2015 
Liver disease in patients awaiting liver transplant
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 13 February 2015 
Prevalence of microscopic colitis
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patientsí colonoscopist selection
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
NAFLD and CVD
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us